The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for intratumoral injections (VAX014) as a single agent as wel…

Advanced Solid TumorAdvanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab

~Estimated

~$10 – $8,750

Vaxiion TherapeuticsNCT05901285

Phase 2

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

To learn if zanzalintinib and pembrolizumab can help to control select subtypes of advanced/metastatic soft-tissue sarcoma (UPS, MFS, HGPS, and HGUS

Phase 2ZanzalintinibPembrolizumab+2 more

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07283731